14日間連日投与法によるrecombinant human granulocyte colony-stimulating factor (rG-CSF)の骨髄異形成症候群に対する血液学的効果

吉田 彌太郎; 平嶋 邦猛; 浅野 茂隆; 高久 史麿; 古沢 新平; 小川 哲平; 有森 茂; 阿部 達生; 鈴木 孝世; 加藤 譲; 藏本 淳; 土肥 博雄; 三好 勇夫; 仁保 喜之; 朝長 万左男

doi:10.11406/rinketsu.32.743

Hematological Effect of 14 Days Treatment of Recombinant Human Granulocyte Colony-Stimulating Factor for Neutropenia in Myelodysplastic Syndromes

Yataro YOSHIDA, Kunitake HIRASHIMA, Shigetaka ASANO, Fumimaro TAKAKU, Shinpei FURUSAWA, Teppei OGAWA, Shigeru ARIMORI, Tatsuo ABE, Takayo SUZUKI, Yuzuru KATO, Atsushi KURAMOTO, Hiroo DOHI, Isao MIYOSHI, Yoshiyuki NIHO, Masao TOMONAGA

Author information

Yataro YOSHIDA
The First Division, Department of Medicine, Faculty of Medicine, Kyoto University
Kunitake HIRASHIMA
The First Department of Internal Medicine, Saitama Medical School
Shigetaka ASANO
Department of Hematology-Oncology, Institute of Medical Science, University of Tokyo
Fumimaro TAKAKU
Department of Hematology-Oncology, Institute of Medical Science, University of Tokyo
Shinpei FURUSAWA
The Third Department of Internal Medicine, Dokkyo University School of Medicine
Teppei OGAWA
Department of Internal Medicine, School of Medicine, Keio University
Shigeru ARIMORI
The Fourth Department of Internal Medicine, School of Medicine, Tokai University
Tatsuo ABE
Department of Hygiene, Kyoto Prefectural University of Medicine
Takayo SUZUKI
Department of Hematologic Internal Medicine, Medical Center for Adult Disease
Yuzuru KATO
The First Department of Internal Medicine, Shimane Medical University
Atsushi KURAMOTO
Department of Internal Medisine Research Institute for Nuclear Medicine and Biology, Hiroshima University
Hiroo DOHI
The Fourth Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital
Isao MIYOSHI
The Third Department of Internal Medicine, Kochi Medical School
Yoshiyuki NIHO
The First Department of Internal Medicine, Faculty of Medicine, Kyusyu University
Masao TOMONAGA
Department of Hematology, Atomic Disease Institute, Nagasaki University

Keywords: myelodysplastic syndromes, granulocyte colony-stimulating factor, neutropenia

JOURNAL RESTRICTED ACCESS

1991 Volume 32 Issue 7 Pages 743-750

DOI https://doi.org/10.11406/rinketsu.32.743

Details

Abstract

Nineteen patients with myelodysplastic syndromes (MDS) were treated with a glycosylated recombinant granulocyte colony-stimulating factor (rG-CSF) for improvement of neutropenia. rG-CSF was administrated intravenously at a dose of 5 μg/kg/day for 14 consecutive days. Most of patients responded to rG-CSF and an approxinately 10 fold increase of the peak neutrophil counts was observed. The neutrophil counts were maintained at high level during the treatment period and returned to pretreatment levels several days after stopping rG-CSF. Consistent with the recovery of neutrophil, infectious complications improved in many cases. Effects of rG-CSF were confined to neutrophils, sparing blast cells and other blood cells. Eruption was observed in one patient as toxicity. We conclude that rG-CSF therapy is effective in improving neutropenia with MDS patients.

Corresponding author

Register with J-STAGE for free!